| 1 |
24018623 | Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes. | 2014 Jan |
1 |
| 2 |
23506134 | Low RPS14 expression in MDS without 5q - aberration confers higher apoptosis rate of nucleated erythrocytes and predicts prolonged survival and possible response to lenalidomide in lower risk non-5q- patients. | 2013 Jun |
2 |
| 3 |
20491881 | Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion. | 2010 Sep |
1 |
| 4 |
19470455 | A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. | 2009 Aug 4 |
1 |